Redeye comments on Ultimovacs’ Q1 2024 report, following its INITIUM top-line failure and announced cost-cutting measures. The company now has a funding runway until Q4 2025e, enabling it to post FOCUS and DOVACC readouts before potentially raising more capital. We judge these readouts to be critical, and negative results would likely erode investor confidence further.

Read more and download the Research Update.
 
Follow companies at Redeye to receive the latest equity research within Life Science and Technology.
 
This is a press release from Redeye - Research Powered Investment Banking. www.redeye.se/